MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01C7EB01.76A7EDC0"
This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer.
------=_NextPart_01C7EB01.76A7EDC0
Content-Location: file:///C:/9282BE47/drugpatchblog.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

Dangers of drug patches overlooked
=
The FDA has cautioned about delivering painkiller fentanyl through the skin, but healthcare providers d=
on't
seem to be getting the message. Other drugs pose problems too.=
span>
By
Ricardo Alonso-Zaldivar, Los Angeles Times Staff
Writer
August 27, 2007
WASHINGTON --
Army Master Sgt. Harold Kinamon entered a milit=
ary
hospital in Ohio for routine respiratory surgery to help him sleep better. =
The
operation, in October 2005, progressed smoothly. He went home with nothing =
more
than a raw throat and a painkiller contained in an adhesive patch on his sk=
in.
That night, Kinamon, 41, di=
ed in
his sleep -- killed by an overdose of the drug delivered through the patch.=
What made his death even more tragic was that the dangers of using skin pat=
ches
to administer the particular painkiller he received, an opiumlike
drug called fentanyl, were clearly understood a=
t the
time. Only three months earlier, the Food and Drug Administration -- respon=
ding
to a number of similar deaths -- had issued a strong warning: Though benefi=
cial
under appropriate conditions, fentanyl patches =
should
be used with great caution, and not for postoperative pain relief.
Kinamon's death reflects more than an individual
misfortune. Healthcare providers nationwide are still not getting the messa=
ge
as fentanyl patches continue to be implicated in
scores of deaths.
Failure to solve the problem is all the more serious because the use of pat=
ches
is spreading to other drugs, including other painkillers, contraceptives and
medications for children with attention deficit disorder. Moreover, a new
generation of high-tech patches is expected to make many more drugs availab=
le
in patch form.
The benefits of patches have been accompanied by problems, replicating a
pattern common to many medical advances: Breakthroughs often come with risks
and downsides that may not be fully recognized until later.
Drug safety experts are urging the FDA to reexamine the issue of medicinal
patches. One primary problem seems to be how to get the right dose of a drug
through a patch for different patients under differing conditions.
Patches are "a neat way of delivering drugs," but they are not an
unalloyed blessing, said Dr. Curt D. Furberg of=
the
Wake Forest University medical school.
The appeal of the patches is clear: They solve a host of problems with more
traditional methods of administering medications. Unlike injections, they d=
on't
hurt. Unlike pills, they don't have to be swallowed. They resolve the common
problem of patients not taking drugs in the right amount at the prescribed
intervals. And their medicine enters the bloodstream directly, rather than =
via
the stomach.
Those advantages are real, medical experts say, but they are not the whole
story.
Sales of Ortho Evra, the first birth-control pa=
tch,
plunged last year after the FDA cautioned that it exposed women to higher
levels of a hormone linked to dangerous blood clots than do oral
contraceptives.
With pills, the drug level spikes after consumption, dropping as the time f=
or
the next dose approaches. Patches maintain a steadier level, but, over time,
this can lead to higher total exposure to the drug. That can cause problems,
and the trade-offs are not well understood, experts say.
"What is the corresponding patch level that would be equivalent to oral
drugs?" Furberg asked. "People use
different formulas and there is disagreement."
The Daytrana patch for attention deficit disord=
er
recently ran into problems. Opening the patch and getting it to stick was d=
ifficult.
(The maker says the adhesion problem has been fixed.) And the medication can
irritate the skin, causing welts. The FDA is investigating.
The effect of any patch can vary considerably from patient to patient.
"Some people may not get enough of the drug, which defeats the purpose=
of
taking it. And some may get too much . . . which is going to hurt some
people," Furberg said.
For instance, heat affects the rate at which the skin absorbs a drug.
Sunbathing, a hot shower or exercise can trigger an overdose.
Also, some people have thicker skin, which is more resistant to absorbing a
drug. Speed of absorption can vary by a factor of about three, which can
complicate finding the right dosage.
Another problem is psychological: Patients and medical professionals have a
tendency to see patches as benign devices akin to a bandage. It's easy to
forget the powerful, potentially dangerous drug within.
"Patches are not innocuous," said Kenneth Sloan, a medicinal chem=
ist
at the University of Florida whose research has shown wide variations in how
quickly individuals absorb drugs through the skin. "One patch does not=
fit
all."
That's why the FDA said in July 2005 that in the case of fentanyl,
patches should be prescribed at the lowest practicable dose, should not be =
used
to treat short-term pain or pain after an operation, and should only be use=
d by
patients already established on opioid drugs. <=
o:p>
IF YOU SUSPECT THAT YOU OR A LOVED ONE HAS BEEN INJUR=
ED AS
A RESULT OF A DRUG PATCH, CONTACT AVERY LAW FIRM FOR A FREE CONSULTATION. IF YOUR CASE IS ACCEPTED, AVERY LA=
W FIRM
WILL HANDLE THE CASE ON A CONTINGENCY FEE BASIS, MEANING THERE IS NO
ATTORNEY’S FEE UNLESS THERE IS A RECOVERY, AND THEN YOU PAY A PERCENT=
AGE
OF THE RECOVERY.
AVERY LAW FIRM
New
York-Colorado-Indiana
&nb=
sp;A Nationally Prominent Personal Injury Law Firm. <=
span
style=3D'font-family:Arial;mso-bidi-font-family:"Times New Roman"'>
=
“Honest,
Experienced, Well Respected.”
ALL
CASES HANDLED ON CONTINGENCY FEE BASIS
NO RECOVERY, NO ATTORNEYS FEES
FREE CONSULTATIONS!
CALL
NOW! 1-866-9-URGENT Toll
free (nationwide)
or (866) 987-4368
Email AVERY LAW FIRM (click here)
Return to HOME=
PAGE
(click here)
------=_NextPart_01C7EB01.76A7EDC0
Content-Location: file:///C:/9282BE47/drugpatchblog_files/image004.jpg
Content-Transfer-Encoding: base64
Content-Type: image/jpeg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------=_NextPart_01C7EB01.76A7EDC0
Content-Location: file:///C:/9282BE47/drugpatchblog_files/image005.jpg
Content-Transfer-Encoding: base64
Content-Type: image/jpeg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------=_NextPart_01C7EB01.76A7EDC0
Content-Location: file:///C:/9282BE47/drugpatchblog_files/image002.png
Content-Transfer-Encoding: base64
Content-Type: image/png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------=_NextPart_01C7EB01.76A7EDC0
Content-Location: file:///C:/9282BE47/drugpatchblog_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"